If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.35    -0.10 (-1.55%)
Bid:
6.30
Ask:
6.40
Spread: 0.10 (1.587%)
Market Cap: £6.56m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half Yearly Results

18 Jul 2014 07:00

RNS Number : 6690M
Ducat Ventures PLC
18 July 2014
 



Ducat Ventures Plc ("Company")

 

Half Yearly Report

 

The Board of Ducat presents the unaudited historical financial information of the Company for the 6 months to 31 May 2014. 

 

Consolidated Statement of Comprehensive Income

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

 to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

Continuing operations

 

 

£

£

 

 

 

 

 

Revenue

 

 

-

-

Cost of Sales

 

 

-

-

 

 

 

───────

───────

 

 

 

 

 

Gross Loss

 

 

-

-

 

 

 

 

 

Administrative expenses

 

 

(57,643)

(166,453)

 

 

 

───────

───────

Operating Loss

 

 

(57,643)

(166,453)

 

 

 

 

 

Non Operating Items

 

 

 

 

Impairment of investments

 

 

-

(500,000)

Impairment of intercompany loans

 

 

-

(1,384,068)

Surplus arising on settlements with trade creditors

 

 

 

-

 

-

 

 

 

───────

───────

 

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Finance Costs

 

 

-

-

 

 

 

───────

───────

Loss Before Tax

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Taxation

 

 

-

-

 

 

 

───────

───────

Total comprehensive income for the period

 

 

 

(57,643)

 

(2,050,521)

 

 

 

═══════

═══════

 

 

 

 

 

Loss per share

 

 

0.006p

2.29p

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

Consolidated Balance Sheet

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

ASSETS

 

 

£

£

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

Trade and other receivables

 

 

10,034

49,077

Cash and cash equivalents

 

 

105,221

4,945

 

 

 

───────

───────

 

 

 

115,255

54,022

 

 

 

───────

───────

 

 

 

 

 

Total Assets

 

 

115,255

54,022

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

Shareholders' Equity

 

 

 

 

Called up share capital

 

 

5,742,586

5,636,083

Share premium

 

 

1,355,502

1,086,875

Share based payment reserve

 

 

27,200

27,200

Retained earnings

 

 

(7,013,950)

(6,830,754)

 

 

 

───────

───────

Total Equity

 

 

111,338

(80,596)

 

 

 

───────

───────

 

 

 

 

 

LIABILITIES

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

 

3,917

134,618

 

 

 

───────

───────

 

 

 

3,917

134,618

 

 

 

───────

───────

Total Equity and Liabilities

 

 

115,255

54,022

 

 

 

══════

═══════

 

 

 

Consolidated statement of changes in equity

For the six months ended May 2014

 

 

 

 

Called up

Share

Capital

 

 

Share

Premium

Share-

Based

Payment

Reserve

 

 

Retained

Earnings

 

 

Total

Equity

 

£

£

£

£

£

 

 

 

 

 

 

Balance at 1 August 2012

5,574,070

838,822

27,200

(4,780,233)

1,659,859

 

 

 

 

 

 

Loss for period

-

-

-

(2,050,521)

(2,050,521)

 

 

 

 

 

 

Issue of shares

62,013

248,053

-

-

310,066

 

───────

──────

──────

───────

───────

Balance at 31 May 2013

5,636,083

1,086,875

27,200

(6,830,754)

(80,596)

 

 

 

 

 

 

Loss for the period

-

-

-

(125,553)

(125,553)

 

 

 

 

 

 

Issue of shares

86,165

215,936

-

-

302,101

 

───────

──────

──────

───────

───────

Balance at 30 November 2013

5,722,248

1,302,811

27,200

(6,956,307)

95,952

 

 

 

 

 

 

Loss for the period

-

-

-

(57,643)

(57,643)

 

 

 

 

 

 

Issue of ordinary shares at £0.0004 per shares less cost

 

20,338

 

52,691

-

 

 

-

 

73,029

 

───────

──────

──────

───────

───────

Balance at 31 May 2014

5,742,586

1,355,502

27,200

(7,013,950)

113,338

 

══════

══════

══════

══════

═══════

 

 

Consolidated Statement of Cash Flows

As at 31 May 2014

 

 

 

 

 

Six months

 to 31 May

2014

Six months 

to 31 May

2013

 

 

(Unaudited)

(Unaudited)

 

 

£

£

 

 

 

 

Cash flows from operating activities

 

 

 

Loss before tax

 

(57,643)

(166,453)

(Increase)/decrease in trade and other

 receivables

 

 

291,233

 

(81,262)

Increase)/decrease in trade and other

payables

 

 

(201,548)

 

(57,416)

 

 

───────

───────

Net cash from operating activities

 

32,042

(305,131)

 

 

───────

───────

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

Issue of equity net of costs

 

73,029

310,067

Finance interest paid

 

-

-

 

 

───────

───────

Net cash from financing activities

 

73,029

310,067

 

 

───────

───────

 

 

 

 

Increase/(decrease) in cash and cash

equivalents

 

 

105,071

 

4,936

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

150

 

9

 

 

───────

───────

Cash and cash equivalents at the end of period

 

 

105,221

 

4,945

 

 

══════

═══════

 

 

 

 

 

Enquiries:

 

For further information, please contact:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Avi Robinson

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Duncan Vasey

020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGMNVNFGDZM
Date   Source Headline
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change
9th Dec 20207:00 amRNSProposed Director appointment and Director change
18th Nov 20207:00 amRNSLicense and supply agreement with Genuine Health
12th Oct 20207:00 amRNSLaunch of weight management products
9th Oct 20202:00 pmRNSInvestor presentation
8th Oct 20207:00 amRNSHead of Quality & Operations appointment
6th Oct 20207:00 amRNSExclusive distribution agreement
5th Oct 202011:05 amRNSSecond Price Monitoring Extn
5th Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSFDA Investigational New Drug authorisation
28th Sep 20207:00 amRNSExclusive distribution agreement
24th Sep 20207:00 amRNSHalf-year Report
22nd Sep 20207:00 amRNSLicense agreement for SlimBiome® Medical in the US
17th Sep 20207:00 amRNSDistributor agreement with Ayalla Marketing
15th Sep 202011:06 amRNSSecond Price Monitoring Extn
15th Sep 202011:00 amRNSPrice Monitoring Extension
15th Sep 20207:00 amRNSSweetBiotix sweet fibres agreement
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
3rd Sep 202011:05 amRNSSecond Price Monitoring Extn
3rd Sep 202011:00 amRNSPrice Monitoring Extension
11th Aug 20207:00 amRNSScientific and commercial development update
5th Aug 20207:00 amRNSExtension of terms for OptiBiome with OptiPharm
30th Jul 20207:00 amRNSExtension of terms for WellBiome with Maxum Foods
23rd Jul 20207:00 amRNSExtension of terms for WellBiome with Agropur
20th Jul 20207:00 amRNSTrading and commercial update
16th Jul 20207:00 amRNSExtension of terms, territories and products
14th Jul 20207:00 amRNSExtension of terms for WellBiome
9th Jul 202011:29 amRNSResult of AGM
6th Jul 20207:00 amRNSExtension of terms for WellBiome
1st Jul 20207:00 amRNSDistribution agreement with Actial Farmaceutica
29th Jun 20207:00 amRNSLaunch of WellBiome
17th Jun 20207:00 amRNSNotice of AGM
3rd Jun 20207:00 amRNSExercise of Warrant
2nd Jun 20203:35 pmRNSGrant of Options
1st Jun 20203:45 pmRNSHolding(s) in Company
1st Jun 20207:00 amRNSCambridge Commodities appointment as distributor
28th May 20207:00 amRNSFinal Results
20th May 20207:00 amRNSLaunch of SlimBiome gummies in USA
18th May 20207:00 amRNSTrading and commercial update
11th May 20207:00 amRNSExclusive distribution agreement with MAXCARE Inc
5th May 20207:00 amRNSDistribution of products in China and Hong Kong
4th May 20207:00 amRNSNon-exclusive agreement with Smart For Life
17th Apr 20204:24 pmRNSHolding(s) in Company
17th Apr 202011:03 amRNSPlacing and Related Party Transaction

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.